Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that
can involve the bone marrow, peripheral blood, skin, lymph nodes, and the central nervous …

In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

Purpose: Treatment outcomes in patients with relapsed/refractory (R/R) myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML) remains dismal. On the basis of both …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy
with a poor prognosis and considered incurable with conventional chemotherapy. Small …

Plasmacytoid dendritic cells (pDCs) are type I interferon-producing cells that modulate
immune responses. There are two types of pDC neoplasms: 1) mature pDC proliferation …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic
malignancy with poor outcomes. The World Health Organization (WHO) redefined BDCN as …

Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly clinically
aggressive, ultra-rare hematologic malignancy. 1 The worldwide incidence is largely …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy
with an aggressive clinical course and poor prognosis. BPDCN is most often characterized …

Inflammation control is critical during the innate immune response. Such response is
triggered by the detection of molecules originating from pathogens or damaged host cells by …